Separately, Zacks Investment Research lowered shares of Transenterix from a buy rating to a sell rating in a research note on Tuesday, August 8th.
Transenterix (NASDAQ:TRXC) traded up 12.66% during mid-day trading on Friday, reaching $3.47. The company had a trading volume of 21,375,810 shares. The firm’s market capitalization is $515.42 million. The firm has a 50-day moving average price of $1.63 and a 200 day moving average price of $0.95. Transenterix has a 12-month low of $0.45 and a 12-month high of $5.00.
COPYRIGHT VIOLATION NOTICE: “Transenterix Inc (TRXC) Given a $5.00 Price Target by Ladenburg Thalmann Financial Services Analysts” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/10/21/transenterix-inc-trxc-given-a-5-00-price-target-by-ladenburg-thalmann-financial-services-analysts.html.
In related news, insider Todd Pope sold 600,000 shares of the business’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total transaction of $2,208,000.00. Following the sale, the insider now owns 462,644 shares of the company’s stock, valued at $1,702,529.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
A number of large investors have recently bought and sold shares of TRXC. Global X Management Co. LLC boosted its stake in Transenterix by 238.3% during the second quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock worth $235,000 after acquiring an additional 233,213 shares in the last quarter. LMR Partners LLP bought a new position in shares of Transenterix in the second quarter worth approximately $189,000. UBS Oconnor LLC bought a new position in shares of Transenterix in the second quarter worth approximately $390,000. Goldman Sachs Group Inc. lifted its stake in shares of Transenterix by 7,137.7% in the second quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock worth $854,000 after buying an additional 1,186,575 shares in the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Transenterix by 17.1% in the second quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock worth $298,000 after buying an additional 61,034 shares in the last quarter.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.